A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

To be considered for this study, you would need to be an adult, aged 18 or older, with a clear diagnosis of psoriatic arthritis that has been active for at least six months. Your arthritis should still be causing significant symptoms, specifically at least five tender and five swollen joints.

You also need to have active skin psoriasis, with at least one patch that is 2cm or larger, or have psoriasis affecting your nails. Crucially, you must have tried and either not responded well to, or had trouble tolerating, other treatments for your arthritis, such as biologic therapies or traditional anti-rheumatic drugs.

There are also some reasons why you might not be able to join. For example, if you've previously had a bad reaction to risankizumab, or if, for any other health reason, the study doctor believes it wouldn't be safe or suitable for you.

If you join this study, it will involve several stages over a long period, potentially up to about six and a half years. Firstly, there's a screening period of about five weeks to check if you're suitable. Once accepted, for the first 24 weeks, you'll be randomly assigned to receive either risankizumab or a dummy treatment (placebo). You won't know which one you're getting, and neither will your study doctor.

After 24 weeks, everyone will receive risankizumab. For some time, you'll still be 'blinded' to what you originally received, but eventually, everyone will receive the active study drug. You'll receive the medicine as injections every 12 weeks. Throughout the study, you'll have regular visits to the clinic for assessments to monitor your arthritis, check for any side effects, and see how you're responding to treatment. There will also be a follow-up phone call about 20 weeks after your last dose of medication.